When it comes back, it comes back with a fury.
In the wake of a pandemic that touched billions, researchers are uncovering a troubling possibility: that viral infections like COVID-19 may not merely threaten the living, but awaken what was thought to be dormant — cancer cells held in check by a balanced immune system. Studies from laboratory mice and large human health databases suggest that the immune upheaval caused by severe infection, particularly the protein storm it unleashes, may tip that balance in ways that allow sleeping cancers to return with unexpected force. The findings are preliminary, contested in their mechanism, and far from settled science, yet they carry a weight that researchers and cancer survivors alike cannot easily set aside. For now, the clearest lesson is an old one rendered newly urgent: for those already vulnerable, prevention of severe infection is not a minor precaution but a potentially life-altering one.
- Cancer survivors who contracted COVID in 2020 faced significantly higher rates of cancer recurrence and death within the following year, with metastatic lung tumors appearing at alarming frequency.
- Laboratory mice carrying dormant breast cancer cells developed aggressive tumors at far higher rates after exposure to COVID or influenza, giving biological weight to what the human data was already suggesting.
- The suspected mechanism — a cytokine storm flooding the body with immune proteins like IL-6, or the suppression of mitochondrial function by SARS-CoV-2 — points to the immune system itself as an unwitting accomplice in cancer's return.
- Researchers remain divided on the precise driver, and none believe COVID directly causes cancer; the virus appears instead to disturb the fragile equilibrium that keeps dormant cancer cells from reawakening.
- With findings still preliminary and peer review incomplete in some cases, scientists are urging caution in interpretation while simultaneously calling for urgent further investigation.
- The actionable consensus is clear even amid scientific uncertainty: vaccination and infection prevention for immunocompromised and cancer-history patients are not optional — they may be lifesaving.
In early 2022, researchers at the University of Colorado made an unsettling discovery: mice carrying dormant breast cancer cells, when exposed to COVID-19 or influenza, developed aggressive lung tumors at dramatically higher rates than uninfected animals. The laboratory finding might have remained a curiosity, but when the team examined real-world data, the pattern held. Cancer survivors who contracted COVID in 2020 — before vaccines existed — were substantially more likely to die from recurring cancer than those who stayed healthy, with risk peaking in the year immediately after infection. A separate U.S. breast cancer database showed similar trends for metastatic lung tumors in women previously in remission.
Lead researcher James DeGregori described the phenomenon starkly: when cancer comes back after viral infection, it comes back with a fury. The pandemic, paradoxically, had created the conditions to see this. With billions infected, statistically significant patterns became visible in datasets that would never otherwise exist — a grim scientific dividend from global catastrophe.
The suspected mechanism centers on the immune system's response to severe infection. Cytokines — proteins that coordinate immune activity — can surge out of control in serious cases, producing what clinicians call a cytokine storm. One protein in particular, interleukin-6 or IL-6, had already been linked to cancer recurrence across multiple tumor types, and in the mice, it was elevated IL-6 that appeared to reactivate dormant breast cancers. A co-author offered a related but distinct explanation: that SARS-CoV-2's unusual efficiency at suppressing mitochondrial function — the cellular machinery that generates energy — might be the true driver, potentially explaining both long COVID's persistent fatigue and unexpected cancer returns.
Researchers were careful to draw a firm line: COVID is not an oncogenic virus. It does not cause cancer the way HPV causes cervical cancer or hepatitis causes liver cancer. What the pandemic appears to have revealed is something subtler — that viral infection can disturb the immune equilibrium that keeps dormant cancer cells in check, allowing them to reawaken in patients who believed themselves in remission.
The science remains early and contested, with some key findings still awaiting peer review. But the practical implication, researchers agreed, is already clear enough: for people with compromised immune systems or cancer histories, avoiding severe infection is not a minor health consideration. Vaccination against COVID, influenza, and RSV offers protection that, in light of these findings, carries new and serious weight.
In early 2022, as the Omicron variant sent COVID cases surging across the country, researchers at the University of Colorado Anschutz Medical Campus made an unsettling discovery in their laboratory. When mice carrying dormant breast cancer cells were exposed to either influenza or SARS-CoV-2, the animals developed aggressive lung tumors at significantly higher rates than their uninfected counterparts. The finding was striking enough on its own. But when James DeGregori's team turned to real-world data, they found something that suggested the laboratory mice were telling them something true about human biology.
Analysis of health records from the U.K. Biobank revealed a pattern: cancer survivors who contracted COVID in 2020—when the virus was novel and vaccines did not yet exist—were substantially more likely to die from recurring cancer than those who never got sick, with the highest risk concentrated in the year immediately following infection. A separate examination of a U.S. breast cancer database showed women in remission who developed COVID were more prone to metastatic lung tumors than those who avoided the virus. The data aligned with the mice. Something about viral infection appeared capable of waking sleeping cancer.
DeGregori described the phenomenon with a phrase that captured its clinical weight: "When it comes back, it comes back with a fury." His hypothesis was that viral infections functioned almost like accelerant on an existing fire. The scale of the pandemic itself had inadvertently created the conditions for this discovery. As Dr. Stanley Perlman, a microbiologist at the University of Iowa who studies coronaviruses, explained, a global outbreak that touched billions of people provided researchers with a denominator they could never otherwise access. The sheer number of infected individuals made statistically significant patterns visible that would have remained hidden in smaller datasets.
The mechanism appeared to center on the immune system's response to severe infection. When the body fights a virus like COVID or influenza, it releases cytokines—proteins that coordinate the immune response. In severe cases, the immune system can overcorrect, flooding the body with excessive cytokines in what clinicians call a cytokine storm. During the early pandemic, researchers documented that hospitalized COVID patients and those who died showed dramatically elevated levels of these proteins, particularly one called interleukin-6, or IL-6. That same protein had been independently linked to cancer recurrence and spread in multiple cancer types. In DeGregori's mice, dormant breast cancers reactivated specifically in response to high IL-6 levels.
Yet even among the researchers publishing these findings, interpretation remained contested. Dr. Doug Wallace, a co-author on the Nature paper where these results appeared, offered a different reading of the data. He argued that IL-6's suppression of mitochondria—the cellular structures that generate energy—was the actual driver of cancer growth. SARS-CoV-2, he noted, appeared particularly efficient at shutting down mitochondrial function, which might explain both the lingering exhaustion of long COVID and the unexpected return of cancer in some patients. Other viruses damaged mitochondria too, but the coronavirus seemed to do it with unusual potency.
Dr. Aditya Bardia, director of Translational Research Integration at UCLA's Jonsson Comprehensive Cancer Center, acknowledged that his own laboratory had observed associations between COVID infection and breast cancer recurrence, though that work had not yet undergone peer review. The evidence, he and others stressed, remained preliminary. No researcher contacted for the article believed COVID was an oncogenic virus—one that directly causes cancer—in the way that human papillomavirus causes cervical cancer or hepatitis B and C cause liver cancer. SARS-CoV-2 lacked the structural characteristics of known cancer-causing viruses. The pandemic had simply revealed that viral infection might play a role in reactivating cancers that already existed in dormant form within a patient's body, held in check by an intact immune system until infection disrupted that balance.
Dr. Eric Winer, director of the Yale Cancer Center, embodied the measured skepticism appropriate to early-stage research. "Interesting finding, let's look more," he said, while acknowledging the question deserved investigation. The practical implication, researchers agreed, was straightforward: people with compromised immune systems or histories of cancer had compelling reason to avoid severe infections of all kinds. Vaccines against COVID, influenza, and respiratory syncytial virus offered protection worth taking seriously. The science was still being written, but the stakes for vulnerable populations were clear enough to warrant precaution.
Citas Notables
When cancer comes back, it comes back with a fury. We think that these virus infections can be almost like fuel for the fire.— James DeGregori, University of Colorado Anschutz Medical Campus
COVID and influenza do not cause cancer themselves, but if you have cancer and you have dormant cancer cells that are normally under control by your immune system, getting a severe case of COVID can help reactivate those existing cancers.— Dr. Patrick Moore, University of Pittsburgh
La Conversación del Hearth Otra perspectiva de la historia
Why would a viral infection wake up cancer that's already dormant? That seems like two separate biological problems.
The immune system normally keeps dormant cancer cells suppressed. When you get a severe viral infection, your body floods itself with inflammatory proteins to fight the virus. In some cases, that same inflammation can reactivate the cancer cells that were being held in check.
So it's not that the virus causes cancer—it's that the virus disrupts the immune system's ability to keep cancer asleep.
Exactly. The virus itself isn't oncogenic. But the body's response to severe infection can be. Specifically, a protein called IL-6 appears to both fuel cancer growth and suppress the mitochondria that give cells energy.
How certain are researchers about this? Does everyone agree on the mechanism?
Not entirely. The data showing the association is real—people who had COVID were more likely to have cancer recurrence. But even the researchers who published the findings disagree on whether it's the inflammatory proteins or the mitochondrial damage doing the damage. It's early.
What should someone who's had cancer do with this information?
Get vaccinated against COVID, flu, and RSV. Avoid severe infections if possible. The mechanism isn't fully understood yet, but the pattern is clear enough that precaution makes sense for people with vulnerable immune systems.